The association and causal role of infectious agents in chronic inflammatory diseases have major implications for public health, treatment, and prevention. Pharmacological treatment of combined infectious and inflammatory diseases requires the administration of multiple drugs, including antibiotics and anti-inflammatory drugs. However, this can cause adverse effects, and therefore, dual-action drugs need to be developed. Anti-inflammatory drugs that have already shown antimicrobial properties appear to be promising candidates. NSAIDs, namely aceclofenac, diclofenac, and ibuprofen, were tested in clinical trials with patients diagnosed with uncomplicated urinary tract infections (UTIs) and cellulitis. The administration of ibuprofen, a drug tested in the highest number of studies, resulted in symptom resolution in patients with UTIs. Additionally, ibuprofen caused a high survival rate in mice infected with Pseudomonas aeruginosa and demonstrated potent in vitro antibacterial effects against Bacillus cereus, Escherichia coli, and Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA) (MIC 0.625-2.5 mg/L). For most anti-inflammatory drugs, only data showing their in vitro and in vivo antimicrobial effects are available. Among these, auranofin caused a high survival rate in mice infected with Enterococcus faecium, S. aureus, and Clostridioides difficile. It also produced a strong in vitro growth-inhibitory effect against Streptococcus agalactiae, S. pneumoniae, S. aureus, S. epidermidis, Bacillus subtilis, C. difficile, E. faecalis, E. faecium, and Mycobacterium tuberculosis (MIC 0.0015-5 mg/L). Similarly, aspirin caused a high survival rate in M. tuberculosis-infected mice and strong to moderate in vitro activity against E. coli, B. cereus, P. aeruginosa, Enterobacter aerogenes, Klebsiella pneumoniae and Salmonella choleraesuis (MIC 1.2-5 mg/L). Moreover, topical application of celecoxib resulted in a high reduction in MRSA burden in mice. However, it only caused moderate in vitro effects against S. epidermidis, S. aureus and Bacillus subitilis (MIC 16-64 mg/L). These data suggest that certain non-steroidal anti-inflammatory drugs (NSAIDs) are promising drug candidates for the development of dual-action drugs for the potential treatment of combined infectious and inflammatory diseases such as tuberculosis, musculoskeletal infections and UTIs. Nevertheless, future clinical trials must be conducted to ascertain the antibacterial effect of these NSAIDs before their practical use.

Department of Crop Sciences and Agroforestry Faculty of Tropical AgriSciences Czech University of Life Sciences Prague Prague Czechia

See more in PubMed

Abbas H. A., Atallah H., El-Sayed M. A., El-Ganiny A. M. (2020). Diclofenac mitigates virulence of multidrug-resistant Staphylococcus aureus . Arch. Microbiol. 202, 2751–2760. 10.1007/s00203-020-01992-y PubMed DOI

Abdel-Aziz M. I., Ali M. A., Hassan A. K., Elfaham T. H. (2016). Warfarin-drug interactions: an emphasis on influence of polypharmacy and high doses of amoxicillin/clavulanate. J. Clin. Pharmacol. 56, 39–46. 10.1002/jcph.583 PubMed DOI

AbdelKhalek A., Abutaleb N. S., Elmagarmid K. A., Seleem M. N. (2018). Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci. Sci. Rep. 8, 8353. 10.1038/s41598-018-26674-0 PubMed DOI PMC

AbdelKhalek A., Abutaleb N. S., Mohammad H., Seleem M. N. (2019). Antibacterial and anti-virulence activities of auranofin against Clostridium difficile . Int. J. Antimicrob. Agents 53, 54–62. 10.1016/j.ijantimicag.2018.09.018 PubMed DOI PMC

Abraham S., Sharon N., Ofek I. (1999). “Adhesion of bacteria to mucosal surfaces,” in Mucosal immunology. Editors Ogra P. L., Mestecky M. J., Lamm M. E., Strober W., Bienenstock J., McGhee J. R. (San Diego: Academic Press; ).

Abraham S., Shin J., Malaviya R. (2001). Type 1 fimbriated Escherichia coli-mast cell interactions in cystitis. J. Infect. Dis. 183 (Suppl. 1), S51–S55. 10.1086/318853 PubMed DOI

Abutaleb N. S., Seleem M. N. (2020a). Anti-virulence activity of auranofin against vancomycin-resistant enterococci: in vitro and in vivo studies. Int. J. Antimicrob. Agents 55, 105828. 10.1016/j.ijantimicag.2019.10.009 PubMed DOI PMC

Abutaleb N. S., Seleem M. N. (2020b). Auranofin, at a clinically achievable dose, protects mice and prevents recurrence from Clostridioides difficile infection. Sci. Rep. 10, 7701. 10.1038/s41598-020-64882-9 PubMed DOI PMC

Al-Bakri A. G., Othman G., Bustanji Y. (2009). The assessment of the antibacterial and antifungal activities of aspirin, EDTA and aspirin-EDTA combination and their effectiveness as antibiofilm agents. J. Appl. Microbiol. 107, 280–286. 10.1111/j.1365-2672.2009.04205.x PubMed DOI

Al-Janabi A. A. (2010). In vitro antibacterial activity of ibuprofen and acetaminophen. J. Glob. Infect. Dis. 2, 105–108. 10.4103/0974-777X.62880 PubMed DOI PMC

Altinkaynak K., Suleyman H., Akçay F. (2003). Effect of nimesulide, rofecoxib and celecoxib on gastric tissue glutathione level in rats with indomethacin-induced gastric ulcerations. Pol. J. Pharmacol. 55, 645–648. PubMed

Alves de Lima e Silva A., Viana A. S., Silva P. M., de Matos Nogueira E., Salgado L. T., Tomazetto de Carvalho R., et al. (2021). Diclofenac may induce PIA-independent biofilm formation in Staphylococcus aureus strains. Int. Microbiol. 2021, 1–11. 10.1155/2021/8823775 DOI

Amgen (2024). Amgen reports fourth quarter and full year 2024 financial results. Available online at: https://www.amgen.com/newsroom/press-releases/2025/02/amgen-reports-fourth-quarter-and-full-year-2024-financial-results (Accessed February 26, 2025).

Amgen Canada Inc (2022). Romosozumab (evenity): CADTH reimbursement review: therapeutic area: osteoporosis. Available online at: https://www.cda-amc.ca/sites/default/files/DRR/2022/SR0676-Evenity-combined-report.pdf (Accessed February 18, 2025). PubMed

Arkader A., Brusalis C., Warner W. C., Jr., Conway J. H., Noonan K. (2016). Update in pediatric musculoskeletal infections: when it is, when it isn't, and what to do. Am. Acad. Orthop. Surg. 24, e112–e121. 10.5435/JAAOS-D-15-00714 PubMed DOI

Ashburn T. T., Thor K. B. (2004). Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673–683. 10.1038/nrd1468 PubMed DOI

Aycan I. O., Elpek O., Akkaya B., Kıraç E., Tuzcu H., Kaya S., et al. (2018). Diclofenac-induced gastrointestinal and renal toxicity is alleviated by thymoquinone treatment. Food Chem. Toxicol. 118, 795–804. 10.1016/j.fct.2018.06.038 PubMed DOI

Bailey J., Thew M., Balls M. (2014). An analysis of the use of animal models in predicting human toxicology and drug safety. Altern. Lab. Anim. 42, 181–199. 10.1177/026119291404200306 PubMed DOI

Ballard C. G. (2002). Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur. Neurol. 47, 64–70. 10.1159/000047952 PubMed DOI

Bausch and Lomb (2022). 4Q22 and FY22 financial results: FY22 financial highlights and segment drivers. Available online at: https://ir.bausch.com/sites/bauschhealth-ir/files/2023-02/4q22-bausch-lomb-earnings-presentation.pdf (Accessed February 18, 2025).

Beck-Broichsitter B. E., Smeets R., Heiland M. (2015). Current concepts in pathogenesis of acute and chronic osteomyelitis. Curr. Opin. Infect. Dis. 8, 240–245. 10.1097/QCO.0000000000000155 PubMed DOI

Bell J. (2019). Aspirin killed the cat: animal research models do not always apply to humans. Expert Opin. Drug Metab. Toxicol. 15, 683–685. 10.1080/17425255.2019.1652596 PubMed DOI

Bettcher C. M., Campbell E., Petty L. A., Rew K. T., Zelnik J. C., Lane G. I., et al. (2021). Urinary tract infection. Michigan, United States Michigan Medicine University of Michigan. Available online at: https://www.ncbi.nlm.nih.gov/books/NBK572335/ (Accessed February 24, 2025) PubMed

Bindu S., Mazumder S., Bandyopadhyay U. (2020). Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective. Biochem. Pharmacol. 180, 114147. 10.1016/j.bcp.2020.114147 PubMed DOI PMC

Blanco-Cabra N., Paetzold B., Ferrar T., Mazzolini R., Torrents E., Serrano L., et al. (2020). Characterisation of different alginate lyases for dissolving Pseudomonas aeruginosa biofilms. Sci. Rep. 10, 9390. 10.1038/s41598-020-66293-2 PubMed DOI PMC

Bleidorn J., Gagyor I., Kochen M. M., Wegscheider K., Hummers-Pradier E. (2010). Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection? results of a randomised controlled pilot trial. BMC Med. 8, 30. 10.1186/1741-7015-8-30 PubMed DOI PMC

Brown D., Superti-Furga G. (2003). Rediscovering the sweet spot in drug discovery. Drug Discov. Today 8, 1067–1077. 10.1016/s1359-6446(03)02902-7 PubMed DOI

Bruneton J. (1999). Quinones. Pharmacognosy, phytochemistry, medicinal plants. 2nd ed. Paris, Lavoisier, 409–444.

Bruniera F. R., Ferreira F. M., Saviolli L. R., Bacci M. R., Feder D., da Luz Goncalves Pedreira M., et al. (2015). The use of vancomycin with its therapeutic and adverse effects: a review. Eur. Rev. Med. Pharmacol. Sci. 19, 694–700. PubMed

Butler C. C., Francis N., Thomas-Jones E., Lloret C., Bongard E., Moore M., et al. (2017). Variations in presentation, management, and patient outcomes of urinary tract infection: a prospective four-country primary care observational cohort study. Br. J. Gen. Pract. 67, e830–e841. 10.3399/bjgp17X693641 PubMed DOI PMC

Byrne S. T., Denkin S. M., Zhang Y. (2007). Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. J. Antimicrob. Chemother. 59, 313–316. 10.1093/jac/dkl486 PubMed DOI

Carr W., Kurbatova E., Starks A., Goswami N., Allen L., Winston C. (2022). Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis - United States, 2022. MMWR Morb. Mortal. Wkly. Rep. 71, 285–289. 10.15585/mmwr.mm7108a1 PubMed DOI

Cassetta M. I., Marzo T., Fallani S., Novelli A., Messori L. (2014). Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections. Biometals 27, 787–791. 10.1007/s10534-014-9743-6 PubMed DOI

Cavalli A., Bolognesi M. L., Minarini A., Rosini M., Tumiatti V., Recanatini M., et al. (2008). Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 51, 347–372. 10.1021/jm7009364 PubMed DOI

Chan E. W. L., Yee Z. Y., Raja I., Yap J. K. Y. (2017). Synergistic effect of non-steroidal anti-inflammatory drugs (NSAIDs) on antibacterial activity of cefuroxime and chloramphenicol against methicillin-resistant Staphylococcus aureus . J. Glob. Antimicrob. Resist 10, 70–74. 10.1016/j.jgar.2017.03.012 PubMed DOI

Chen Q., Ilanga M., Simbassa S. B., Chirra B., Shah K. N., Cannon C. L. (2023). Synergistic antimicrobial effects of ibuprofen combined with standard-of-care antibiotics against cystic fibrosis pathogens. Biomedicines 11, 2936. 10.3390/biomedicines11112936 PubMed DOI PMC

Chen Z., Cheng L., Feng G. (2018). Bone inflammation and chronic recurrent multifocal osteomyelitis. Eur. Rev. Med. Pharmacol. Sci. 22, 1380–1386. 10.26355/eurrev_201803_14482 PubMed DOI

Chiaverini L., Pratesi A., Cirri D., Nardinocchi A., Tolbatov I., Marrone A., et al. (2022). Anti-staphylococcal activity of the auranofin analogue bearing acetylcysteine in place of the thiosugar: an experimental and theoretical investigation. Molecules 27, 2578. 10.3390/molecules27082578 PubMed DOI PMC

Chiu H. C., Lee S. L., Kapuriya N., Wang D., Chen Y. R., Yu S. L., et al. (2012). Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus . Bioorg Med. Chem. 20, 4653–4660. 10.1016/j.bmc.2012.06.018 PubMed DOI PMC

Chiu H. C., Yang J., Soni S., Kulp S. K., Gunn J. S., Schlesinger L. S., et al. (2009). Pharmacological exploitation of an off-target antibacterial effect of the cyclooxygenase-2 inhibitor celecoxib against Francisella tularensis. Antimicrob Agents Chemother . Antimicrob. Agents Chemother. 53, 2998–3002. 10.1128/AAC.00048-09 PubMed DOI PMC

Chowdhury B., Adak M., Bose S. K. (2003). Flurbiprofen, a unique non-steroidal anti-inflammatory drug with antimicrobial activity against Trichophyton, Microsporum and Epidermophyton species. Antimicrob. Agents Chemother. 64, 158–161. 10.1046/j.1472-765x.2003.01370.x PubMed DOI

Chung H. (2016). The association between chronic inflammation and recurrent cystitis in women. Urogenit. Tract. Infect. 11, 86–92. 10.14777/uti.2016.11.3.86 DOI

Colgan R., Williams M. (2011). Diagnosis and treatment of acute uncomplicated cystitis. Am. Fam. Physician 84, 771–776. PubMed

Colston J., Atkins B. (2018). Bone and joint infection. Clin. Med. (Lond). 18, 150–154. 10.7861/clinmedicine.18-2-150 PubMed DOI PMC

Copley L. A. (2009). Pediatric musculoskeletal infection: trends and antibiotic recommendations. J. Am. Acad. Orthop. Surg. 17, 618–626. 10.5435/00124635-200910000-00004 PubMed DOI

Court M. H. (2013). Feline drug metabolism and disposition: pharmacokinetic evidence for species differences and molecular mechanisms. Vet. Clin. North Am. Small Anim. Pract. 43, 1039–1054. 10.1016/j.cvsm.2013.05.002 PubMed DOI PMC

Cramton S. E., Gerke C., Schnell N. F., Nichols W. W., Gotz F. (1999). The intercellular adhesion (ica) locus is present in Staphylococcus aureus and is required for biofilm formation. Infect. Immun. 67, 5427–5433. 10.1128/IAI.67.10.5427-5433.1999 PubMed DOI PMC

Dai L., Wu T. Q., Xiong Y. S., Ni H. B., Ding Y., Zhang W. C., et al. (2019). Ibuprofen-mediated potential inhibition of biofilm development and quorum sensing in Pseudomonas aeruginosa . Life Sci. 237, 116947. 10.1016/j.lfs.2019.116947 PubMed DOI

Dall L., Peterson S., Simmons T., Dall A. (2005). Rapid resolution of cellulitis in patients managed with combination antibiotic and anti-inflammatory therapy. Cutis 75, 177–180. PubMed

Dang Y., Guan J. (2020). Nanoparticle-based drug delivery systems for cancer therapy. Smart Mater Med. 1, 10–19. 10.1016/j.smaim.2020.04.001 PubMed DOI PMC

Dastidar S. G., Ganguly K., Chaudhuri K., Chakrabarty A. N. (2000). The anti-bacterial action of diclofenac shown by inhibition of DNA synthesis. Int. J. Antimicrob. Agents 14, 249–251. 10.1016/s0924-8579(99)00159-4 PubMed DOI

Davies N. M. (1998). Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin. Pharmacokinet. 34, 101–154. 10.2165/00003088-199834020-00002 PubMed DOI

Davis A., Fassassi C., Dove D., Drapkin J., Likourezos A., Gohel A., et al. (2022). Analgesic efficacy of oral aspirin/ketamine combination for management of acute musculoskeletal pain in the emergency department - a proof-of-concept pilot study. J. Emerg. Med. 62, 750–759. 10.1016/j.jemermed.2022.01.029 PubMed DOI

Davis J. S., Mackrow C., Binks P., Fletcher W., Dettwiller P., Marshall C., et al. (2017). A double-blind randomized controlled trial of ibuprofen compared to placebo for uncomplicated cellulitis of the upper or lower limb. Clin. Microbiol. Infect. 23, 242–246. 10.1016/j.cmi.2017.02.036 PubMed DOI

de Matos R. F., Mendonca L. C. V., da Silva Souza K. G., Fonseca A. A. D., Costa E. M. S., de Lima M. V. D., et al. (2017). Nimesulide inhibits pathogenic fungi: PGE2-dependent mechanisms. Folia Microbiol. (Praha) 62, 169–174. 10.1007/s12223-016-0483-6 PubMed DOI

Demirag M. K., Esen S., Zivalioglu M., Leblebicioglu H., Keceligil H. T. (2007). The effect of aspirin on adherence of slime-producing, coagulase-negative staphylococci to vascular grafts. Ann. Vasc. Surg. 21, 464–467. 10.1016/j.avsg.2006.06.006 PubMed DOI

Dinescu S. C., Barbulescu A. L., Firulescu S. C., Chisalau A. B., Parvanescu C. D., Ciurea P. L., et al. (2021). Staphylococcus aureus-induced septic arthritis of the ankle related to malum perforans in a diabetes patient. Rom. J. Morphol. Embryol. 62, 615–619. 10.47162/RJME.62.2.31 PubMed DOI PMC

Dogan A., Otlu S., Celebi O., Aksu P., Saglam A. G., Dogan A. N. C., et al. (2017). An investigation of antibacterial effects of steroids. Turk. J. Vet. Anim. Sci. 41, 22. 10.3906/vet-1510-24 DOI

Domingos O. D. S., Alcantara B. G. V., Santos M. F. C., Maiolini T. C. S., Dias D. F., Baldim J. L., et al. (2019). Anti-inflammatory derivatives with dual mechanism of action from the metabolomic screening of Poincianella pluviosa . Molecules 24, 4375. 10.3390/molecules24234375 PubMed DOI PMC

Dutta N. K., Annadurai S., Mazumdar K., Dastidar S. G., Kristiansen J., Ec Molnar J., et al. (2007b). Potential management of resistant microbial infections with a novel non-antibiotic: the anti-inflammatory drug diclofenac sodium. Int. J. Antimicrob. Agents 30, 242–249. 10.1016/j.ijantimicag.2007.04.018 PubMed DOI

Dutta N. K., Mazumdar K., Dastidar S. G., Park J. H. (2007a). Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice. Int. J. Antimicrob. Agents 30, 336–340. 10.1016/j.ijantimicag.2007.04.016 PubMed DOI

Elmesseri R. A., Saleh S. E., Ghobish S. A., Majrashi T. A., Elsherif H. M., Aboshanab K. M. (2023). Diclofenac and meloxicam exhibited anti-virulence activities targeting staphyloxanthin production in methicillin-resistant Staphylococcus aureus . Antibiot. (Basel) 12, 277. 10.3390/antibiotics12020277 PubMed DOI PMC

El-Mowafy S. A., Abd El Galil K. H., El-Messery S. M., Shaaban M. I. (2014). Aspirin is an efficient inhibitor of quorum sensing, virulence and toxins in Pseudomonas aeruginosa . Microb. Pathog. 74, 25–32. 10.1016/j.micpath.2014.07.008 PubMed DOI

Ershad M., Ameer M. A., Chen R. J., Vearrier D. (2024). “Ibuprofen toxicity,” in StatPearls (Florida, United States StatPearls Publishing; ). Available online at: https://www.ncbi.nlm.nih.gov/books/NBK526078/(Accessed February 23, 2025). PubMed

Esmail A., Sabur N. F., Okpechi I., Dheda K. (2018). Management of drug-resistant tuberculosis in special sub-populations, including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill. J. Thorac. Dis. 10, 3102–3118. 10.21037/jtd.2018.05.11 PubMed DOI PMC

European Medicine Agency (2013). New safety advice for diclofenac–CMDh endorses PRAC recommendation. Available online at: https://www.ema.europa.eu/en/news/new-safety-advice-diclofenac-cmdh-endorses-prac-recommendation (Accessed February 22, 2025).

Fahey T., Webb E., Montgomery A. A., Heyderman R. S. (2003). Clinical management of urinary tract infection in women: a prospective cohort study. Fam. Pract. 20, 1–6. 10.1093/fampra/20.1.1 PubMed DOI

Farrell B., Pottie K., Thompson W., Boghossian T., Pizzola L., Rashid F. J., et al. (2017). Deprescribing proton pump inhibitors: evidence-based clinical practice guideline. Can. Fam. Physician 63, 354–364. PubMed PMC

FDA (2019). Aspirin for reducing your risk of heart attack and stroke: know the facts: information on using aspirin daily, over-the-counter, with other medicines, as well as its side effects. Available online at: https://www.fda.gov/drugs/safe-use-aspirin/aspirin-reducing-your-risk-heart-attack-and-stroke-know-facts (Accessed February 23, 2025).

Ferrara G., Petrillo M. G., Giani T., Marrani E., Filippeschi C., Oranges T., et al. (2019). Clinical use and molecular action of corticosteroids in the pediatric age. Int. J. Mol. Sci. 20, 444. 10.3390/ijms20020444 PubMed DOI PMC

Ferretti C., Chiaverini L., Poma N., Dalli A., Di Leo R., Rindi L., et al. (2025). Antimicrobial and antibiofilm activity of auranofin and its two derivatives bearing naproxen and acetylcysteine as ligands against Staphylococci . Antibiotics 14, 118. 10.3390/antibiotics14020118 PubMed DOI PMC

Fidelix T. S., Macedo C. R., Maxwell L. J., Fernandes Moca Trevisani V. (2014). Diacerein for osteoarthritis. Cochrane Database Syst. Rev. 2014, CD005117. 10.1002/14651858.CD005117.pub3 PubMed DOI PMC

Field T. S., Gurwitz J. H., Harrold L. R., Rothschild J., DeBellis K. R., Seger A. C., et al. (2004). Risk factors for adverse drug events among older adults in the ambulatory setting. J. Am. Geriatr. Soc. 52, 1349–1354. 10.1111/j.1532-5415.2004.52367.x PubMed DOI

FitzGerald G. A. (2003). COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov. 2, 879–890. 10.1038/nrd1225 PubMed DOI

Flores-Mireles A. L., Walker J. N., Caparon M., Hultgren S. J. (2015). Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 13, 269–284. 10.1038/nrmicro3432 PubMed DOI PMC

Gagyor I., Bleidorn J., Kochen M. M., Schmiemann G., Wegscheider K., Hummers-Pradier E. (2015). Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ 351, h6544. 10.1136/bmj.h6544 PubMed DOI PMC

Gajdacs M., Spengler G. (2019). The role of drug repurposing in the development of novel antimicrobial drugs: non-antibiotic pharmacological agents as quorum sensing-inhibitors. Antibiot. (Basel) 8, 270. 10.3390/antibiotics8040270 PubMed DOI PMC

Ghofrani H. A., Osterloh I. H., Grimminger F. (2006). Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat. Rev. Drug Discov. 5, 689–702. 10.1038/nrd2030 PubMed DOI PMC

Goldenberg D. L. (1998). Septic arthritis. Lancet 351, 197–202. 10.1016/S0140-6736(97)09522-6 PubMed DOI

Gomez-Acebo I., Dierssen-Sotos T., de Pedro M., Perez-Gomez B., Castano-Vinyals G., Fernández-Villa T., et al. (2018). Epidemiology of non-steroidal anti-inflammatory drugs consumption in Spain. The MCC-Spain study. BMC public health 18, 1134. 10.1186/s12889-018-6019-z PubMed DOI PMC

Gustafson J. E., Candelaria P. V., Fisher S. A., Goodridge J. P., Lichocik T. M., McWilliams T., et al. (1999). Growth in the presence of salicylate increases fluoroquinolone resistance in Staphylococcus aureus . Antimicrob. Agents Chemother. 43, 990–992. 10.1128/AAC.43.4.990 PubMed DOI PMC

Hamed M. M., El-Dean A. M., Abdel-Mohsen S. A., Tolba M. S. (2021). New diclofenac derivatives as anti-microbial, anti-inflammatory agents: design, synthesis, biological screening, and molecular docking study. Russ. J. Bioorg Chem. 47, 208–220. 10.1134/S1068162021010088 DOI

Hannan T. J., Totsika M., Mansfield K. J., Moore K. H., Schembri M. A., Hultgren S. J. (2012). Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol. Rev. 36, 616–648. 10.1111/j.1574-6976.2012.00339.x PubMed DOI PMC

Harbut M. B., Vilcheze C., Luo X., Hensler M. E., Guo H., Yang B., et al. (2015). Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis. Proc. Natl. Acad. Sci. U. S. A. 112, 4453–4458. 10.1073/pnas.1504022112 PubMed DOI PMC

Hogan A., Heppert V. G., Suda A. J. (2013). Osteomyelitis. Arch. Orthop. Trauma Surg. 133, 1183–1196. 10.1007/s00402-013-1785-7 PubMed DOI

Hooton T. M. (2012). Clinical practice. Uncomplicated urinary tract infection. N. Engl. J. Med. 366, 1028–1037. 10.1056/NEJMcp1104429 PubMed DOI

Horseman M., Bowman J. D. (2013). Is community-acquired methicillin-resistant Staphylococcus aureus coverage needed for cellulitis? Infect. Dis. Ther. 2, 175–185. 10.1007/s40121-013-0019-1 PubMed DOI PMC

Howes L. G. (2007). Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice? Ther. Clin. Risk Manag. 3, 831–845. PubMed PMC

Humphries R. M., Pollett S., Sakoulas G. A. (2013). A current perspective on daptomycin for the clinical microbiologist. Clin. Microbiol. Rev. 26, 759–780. 10.1128/CMR.00030-13 PubMed DOI PMC

Ito K., Nishida Y., Hamada S., Shimizu K., Sakai T., Ohkawara B., et al. (2022). Efficacy of auranofin as an inhibitor of desmoid progression. Sci. Rep. 12, 11918. 10.1038/s41598-022-15756-9 PubMed DOI PMC

Ivanyi J., Zumla A. (2013). Nonsteroidal anti-inflammatory drugs for adjunctive tuberculosis treatment. J. Infect. Dis. 208, 185–188. 10.1093/infdis/jit153 PubMed DOI

Kalinka J., Hachmeister M., Geraci J., Sordelli D., Hansen U., Niemann S., et al. (2014). Staphylococcus aureus isolates from chronic osteomyelitis are characterized by high host cell invasion and intracellular adaptation, but still induce inflammation. Int. J. Med. Microbiol. 304, 1038–1049. 10.1016/j.ijmm.2014.07.013 PubMed DOI

Kamb A., Wee S., Lengauer C. (2007). Why is cancer discovery so difficult? Nat. Rev. Drug Discov. 6, 115–120. 10.1038/nrd2155 PubMed DOI

Kandiah N., Pai M. C., Senanarong V., Looi I., Ampil E., Park K. W., et al. (2017). Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia. Clin. Interv. Aging 12, 697–707. 10.2147/CIA.S129145 PubMed DOI PMC

Karin M., Lawrence T., Nizet V. (2006). Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124, 823–835. 10.1016/j.cell.2006.02.016 PubMed DOI

Kavanagh N., Ryan E. J., Widaa A., Sexton G., Fennell J., O'Rourke S., et al. (2018). Staphylococcal osteomyelitis: disease progression, treatment challenges, and future directions. Clin. Microbiol. Rev. 31, 000844-17. 10.1128/CMR.00084-17 PubMed DOI PMC

Khazaeinia T., Jamali F. (2000). Evaluation of gastrointestinal toxicity of ibuprofen using surrogate markers in rats: effect of formulation and route of administration. Clin. Exp. Rheumatol. 18, 187–192. PubMed

Kishore N., Raja M. D., Kumar C. S., Dhanalekshmi U., Srinivasan R. (2016). Lipid carriers for delivery of celecoxib: in vitro, in vivo assessment of nanomedicine in rheumatoid arthritis. Eur. J. Lipid Sci. Technol. 118, 949–958. 10.1002/ejlt.201400658 DOI

Ko K., Lee W. K., Oh C. Y., Lee S. H., Cho S. T., Bang W. J., et al. (2018). Is a combination of antibiotics and non-steroidal anti-inflammatory drugs more beneficial than antibiotic monotherapy for the treatment of female acute uncomplicated cystitis? A randomised controlled pilot study. Urol. J. 15, 365–369. 10.22037/uj.v0i0.3716 PubMed DOI

Kolinsky D. C., Liang S. Y. (2018). Musculoskeletal infections in the emergency department. Emerg. Med. Clin. North Am. 36, 751–766. 10.1016/j.emc.2018.06.006 PubMed DOI PMC

Kowalski M. L., Stevenson D. D. (2013). Classification of reactions to non-steroidal anti-inflammatory drugs. Allergy Clin. North Am. 33, 135–145. 10.1016/j.iac.2012.10.008 PubMed DOI

Krasselt M., Baerwald C., Petros S., Seifert O. (2021). Mortality of sepsis in patients with rheumatoid arthritis: a single-center retrospective analysis and comparison with a control group. J. Intensive Care Med. 36, 766–774. 10.1177/0885066620917588 PubMed DOI PMC

Kroesen V. M., Groschel M. I., Martinson N., Zumla A., Maeurer M., van der Werf T. S., et al. (2017). Non-steroidal anti-inflammatory drugs as host-directed therapy for tuberculosis: a systematic review. Front. Immunol. 8, 772. 10.3389/fimmu.2017.00772 PubMed DOI PMC

Kroesen V. M., Rodriguez-Martinez P., Garcia E., Rosales Y., Diaz J., Martin-Cespedes M., et al. (2018). A beneficial effect of low-dose aspirin in a murine model of active tuberculosis. Front. Immunol. 9, 798. 10.3389/fimmu.2018.00798 PubMed DOI PMC

Kronenberg A., Butikofer L., Odutayo A., Muhlemann K., da Costa B. R., Battaglia M., et al. (2017). Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double-blind trial. BMJ 359, j4784. 10.1136/bmj.j4784 PubMed DOI PMC

Kucukguzel S. G., Senkardes S. (2015). Recent advances in bioactive pyrazoles. Eur. J. Med. Chem. 97, 786–815. 10.1016/j.ejmech.2014.11.059 PubMed DOI

Kudva A., Kamath A. T., Dhara V., Ravindranath V. (2019). Chronic recurrent osteomyelitis: a surgeon's enigma. J. Oral Pathol. Med. 48, 180–184. 10.1111/jop.12814 PubMed DOI

Langley G. (2009). The validity of animal experiments in medical research. RSDA 1, 161–168.

Lapi F., Azoulay L., Yin H., Nessim S. J., Suissa S. (2013). Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ 346, e8525. 10.1136/bmj.e8525 PubMed DOI PMC

Laudy A. E. (2018). Non-antibiotics, efflux pumps and drug resistance of Gram-negative rods. Pol. J. Microbiol. 67, 129–135. 10.21307/pjm-2018-017 PubMed DOI PMC

Lawn S. D., Zumla A. I. (2011). Tuberculosis. Lancet 378, 57–72. 10.1016/S0140-6736(10)62173-3 PubMed DOI

Le Berre R., Faure K., Nguyen S., Pierre M., Ader F., Guery B. (2006). Quorum sensing: une nouvelle cible thérapeutique pour Pseudomonas aeruginosa [quorum sensing: a new clinical target for Pseudomonas aeruginosa?]. Med. Mal. Infect. 36, 349–357. 10.1016/j.medmal.2006.01.008 PubMed DOI

Levison M. E., Kaye D. (2013). Treatment of complicated urinary tract infections with an emphasis on drug-resistant gram-negative uropathogens. Curr. Infect. Dis. Rep. 15, 109–115. 10.1007/s11908-013-0315-7 PubMed DOI

Lew D. P., Waldvogel F. A. (2004). Osteomyelitis. Lancet 364, 369–379. 10.1016/S0140-6736(04)16727-5 PubMed DOI

Li J. T., Li Z. S., Zhan X. B., Cui Z. M., Nie S. N. (2003). Experimental study of the safety of the selective COX-2 inhibitor, celecoxib, for gastric mucosa. Chin. J. Dig. Dis. 4, 53–56. 10.1046/j.1443-9573.2003.t01-1-00115.x DOI

Liao X., Yang F., Li H., So P. K., Yao Z., Xia W., et al. (2017). Targeting the thioredoxin reductase-thioredoxin system from Staphylococcus aureus by silver ions. Inorg. Chem. 56, 14823–14830. 10.1021/acs.inorgchem.7b01904 PubMed DOI

Lichtenberger P., Hooton T. M. (2008). Complicated urinary tract infections. Curr. Infect. Dis. Rep. 10, 499–504. 10.1007/s11908-008-0081-0 PubMed DOI

Lima A. L., Oliveira P. R., Carvalho V. C., Cimerman S., Savio E. (2014). Recommendations for the treatment of osteomyelitis. Braz J. Infect. Dis. 18, 526–534. 10.1016/j.bjid.2013.12.005 PubMed DOI PMC

Liu Q. Y., Han F., Pan L. P., Jia H. Y., Li Q., Zhang Z. D. (2018). Inflammation responses in patients with pulmonary tuberculosis in an intensive care unit. Exp. Ther. Med. 15, 2719–2726. 10.3892/etm.2018.5775 PubMed DOI PMC

Mahalmani V., Prakash A., Medhi B. (2023). Do alternatives to animal experimentation replace preclinical research? Indian J. Pharmacol. 55, 71–75. 10.4103/ijp.ijp_223_23 PubMed DOI PMC

Mahmoud E. S., Baharoon S. A., Alsafi E., Al-Jahdaly H. (2016). Acute respiratory distress syndrome complicating community-acquired pneumonia secondary to Mycobacterium tuberculosis in a tertiary care centre in Saudi Arabia. Saudi Med. J. 37, 973–978. 10.15537/smj.2016.9.15183 PubMed DOI PMC

March-Vila E., Pinzi L., Sturm N., Tinivella A., Engkvist O., Chen H., et al. (2017). On the integration of in silico drug design methods for drug repurposing. Front. Pharmacol. 8, 298. 10.3389/fphar.2017.00298 PubMed DOI PMC

Martic-Kehl M. I., Schibli R., Schubiger P. A. (2012). Can animal data predict human outcome? problems and pitfalls of translational animal research. Eur. J. Nucl. Med. Mol. Imaging 39, 1492–1496. 10.1007/s00259-012-2175-z PubMed DOI PMC

Melnyk A. I., Meckes N., Zyczynski H. M., Grosse P. J., Guirguis M., Bradley M. S. (2024). Antibiotic utilization and symptom improvement in a retrospective cohort of women with urinary tract infection symptoms. Int. Urogynecol J. 35, 355–361. 10.1007/s00192-023-05676-1 PubMed DOI PMC

Mendelsohn A. (2022). New dual-action glaucoma medication promising for glaucoma patients. Available online at: https://glaucoma.org/articles/new-dual-action-glaucoma-medication-promising-for-glaucoma-patients (Accessed February 26, 2025).

Millecam J., van Bergen T., Schauvliege S., Antonissen G., Martens A., Chiers K., et al. (2019). Developmental pharmacokinetics and safety of ibuprofen and its enantiomers in the conventional pig as potential pediatric animal model. Front. Pharmacol. 10, 505. 10.3389/fphar.2019.00505 PubMed DOI PMC

Mingh J. (2007). xPharm: the comprehensive pharmacology reference. Elsevier, 1–6. 10.1016/B978-008055232-3.61268-1 DOI

Mohammad H., Abutaleb N. S., Dieterly A. M., Lyle L. T., Seleem M. N. (2021). Investigating auranofin for the treatment of infected diabetic pressure ulcers in mice and dermal toxicity in pigs. Sci. Rep. 11, 10935. 10.1038/s41598-021-90360-x PubMed DOI PMC

National Institute for Health and Care Excellence (2018). Urinary tract infection (lower): antimicrobial prescribing. Available online at: https://www.nice.org.uk/guidance/ng109/resources/urinary-tract-infection-lower-antimicrobial-prescribing-pdf-66141546350533 (Accessed October 23, 2024). PubMed

National Institute for Health and Care Excellence (2022). Resource impact report: romosozumab for treating severe osteoporosis (TA791). Available online at: https://www.nice.org.uk/guidance/ta791/resources/resource-impact-report-pdf-11075818141 (Accessed February 18, 2025).

Nguon S., Novy P., Kokoska L. (2013). Potentiation of the in vitro anti-staphylococcal effect of oxacillin and tetracycline by the anti-inflammatory drug diacetyl rhein. Chemotherapy 59, 447–452. 10.1159/000363730 PubMed DOI

Nielubowicz G. R., Mobley H. L. (2010). Host-pathogen interactions in urinary tract infection. Nat. Rev. Urol. 7, 430–441. 10.1038/nrurol.2010.101 PubMed DOI

Nugrahani I., Herawati D., Wibowo M. S. (2023). The benefits and challenges of antibiotics–non-steroidal anti-inflammatory drugs non-covalent reaction. Molecules 28, 3672. 10.3390/molecules28093672 PubMed DOI PMC

Ohshita Y., Hiramatsu K., Yokota T. (1990). A point mutation in norA gene is responsible for quinolone resistance in Staphylococcus aureus . Biochem. Biophys. Res. Commun. 172, 1028–1034. 10.1016/0006-291x(90)91549-8 PubMed DOI

Okpala O. E., Rondevaldova J., Osei-Owusu H., Kudera T., Kokoskova and T., Kokoska L. (2024). Susceptibility of Staphylococcus aureus to anti-inflammatory drugs with a focus on the combinatory effect of celecoxib with oxacillin in vitro . Molecules 29, 3665. 10.3390/molecules29153665 PubMed DOI PMC

Oliveira I. M., Borges A., Borges F., Simoes M. (2019). Repurposing ibuprofen to control Staphylococcus aureus biofilms. Eur. J. Med. Chem. 166, 197–205. 10.1016/j.ejmech.2019.01.046 PubMed DOI

Ornelas A., Zacharias-Millward N., Menter D. G., Davis J. S., Lichtenberger L., Hawke D., et al. (2017). Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev. 36, 289–303. 10.1007/s10555-017-9675-z PubMed DOI PMC

Ozturk I., Eraç Y., Ballar Kırmızibayrak P., Ermertcan S. (2021). Non-steroidal anti-inflammatory drugs alter antibiotic susceptibility and expression of virulence-related genes and protein A of Staphylococcus aureus . Turk J. Med. Sci. 51, 835–847. 10.3906/sag-2003-60 PubMed DOI PMC

Page A. T., Clifford R. M., Potter K., Schwartz D., Etherton-Beer C. D. (2016). The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br. J. Clin. Pharmacol. 82, 583–623. 10.1111/bcp.12975 PubMed DOI PMC

Pallio G., Bitto A., Pizzino G., Galfo F., Irrera N., Minutoli L., et al. (2016). Use of a balanced dual cyclooxygenase-1/2 and 5-lypoxygenase inhibitor in experimental colitis. Eur. J. Pharmacol. 789, 152–162. 10.1016/j.ejphar.2016.07.033 PubMed DOI

Patyar S., Prakash A., Medhi B. (2011). Dual inhibition: a novel promising pharmacological approach for different disease conditions. J. Pharm. Pharmacol. 63, 459–471. 10.1111/j.2042-7158.2010.01236.x PubMed DOI

Pavelka K., Bruyere O., Cooper C., Kanis J. A., Leeb B. F., Maheu E., et al. (2016). Diacerein: benefits, risks and place in the management of osteoarthritis. An opinion-based report from the ESCEO. Drugs Aging 33, 75–85. 10.1007/s40266-016-0347-4 PubMed DOI PMC

Pereira P. A., Trindade B. C., Secatto A., Nicolete R., Peres-Buzalaf C., Ramos S. G., et al. (2013). Celecoxib improves host defense through prostaglandin inhibition during Histoplasma capsulatum infection. Mediat. Inflamm. 2013, 950981. 10.1155/2013/950981 PubMed DOI PMC

Pina-Vaz C., Sansonetty F., Rodrigues A. G., Martinez-DE-Oliveira J., Fonseca A. F., Mardh P. A. (2000). Antifungal activity of ibuprofen alone and in combination with fluconazole against Candida species. J. Med. Microbiol. 49, 831–840. 10.1099/0022-1317-49-9-831 PubMed DOI

Pinzi L., Bisi N., Rastelli G. (2024). How drug repurposing can advance drug discovery: challenges and opportunities. Front. Drug Discov. 4, 1460100. 10.3389/fddsv.2024.1460100 DOI

Powell L. C., Pritchard M. F., Ferguson E. L., Powell K. A., Patel S. U., Rye P. D., et al. (2018). Targeted disruption of the extracellular polymeric network of Pseudomonas aeruginosa biofilms by alginate oligosaccharides. NPJ Biofilms Microbiomes 4, 13. 10.1038/s41522-018-0056-3 PubMed DOI PMC

Quadros Barse L., Ulfig A., Varatnitskaya M., Vázquez-Hernández M., Yoo J., Imann A. M., et al. (2024). Comparison of the mechanism of antimicrobial action of the gold(I) compound auranofin in Gram-positive and Gram-negative bacteria. Microbiol. Spectr. 12, e0013824. 10.1128/spectrum.00138-24 PubMed DOI PMC

Ratia C., Soengas R. G., Soto S. M. (2022). Gold-derived molecules as new antimicrobial agents. Front. Microbiol. 13, 846959. 10.3389/fmicb.2022.846959 PubMed DOI PMC

Rayaprolu B. M., Strawser J. J., Anyarambhatla G. (2018). Excipients in parenteral formulations: selection considerations and effective utilization with small molecules and biologics. Drug Dev. Ind. Pharm. 44, 1565–1571. 10.1080/03639045.2018.1483392 PubMed DOI

Reeve E., Gnjidic D., Long J., Hilmer S. (2015). A systematic review of the emerging definition of 'deprescribing' with network analysis: implications for future research and clinical practice. Br. J. Clin. Pharmacol. 80, 1254–1268. 10.1111/bcp.12732 PubMed DOI PMC

Richeldi L., Ewer K., Losi M., Hansell D. M., Roversi P., Fabbri L. M., et al. (2004). Early diagnosis of subclinical multidrug-resistant tuberculosis. Ann. Intern Med. 140, 709–713. 10.7326/0003-4819-140-9-200405040-00010 PubMed DOI

Sachdeva A., Nambiar A., Rai B. P., Veeratterapillay R., Harding C. (2021). Non‐steroidal anti‐inflammatory drugs for treating symptomatic uncomplicated urinary tract infections in non‐pregnant adult women. Cochrane Database Syst. Rev. 2021, CD014762. 10.1002/14651858.CD014762 PubMed DOI PMC

Sasindran S. J., Torrelles J. B. (2011). Mycobacterium tuberculosis infection and inflammation: what is beneficial for the host and for the bacterium? Front. Microbiol. 2, 2. 10.3389/fmicb.2011.00002 PubMed DOI PMC

Scottish Intercollegiate Guidelines Network (2020). Management of suspected bacterial lower urinary tract infection in adult women. Edinburgh: SIGN. Available online at: https://www.sign.ac.uk/media/1766/sign-160-uti-0-1_web-version.pdf (Accessed October 23, 2024).

Sedlacek M., Gemery J. M., Cheung A. L., Bayer A. S., Remillard B. D. (2007). Aspirin treatment is associated with a significantly decreased risk of Staphylococcus aureus bacteremia in hemodialysis patients with tunneled catheters. Am. J. Kidney Dis. 49, 401–408. 10.1053/j.ajkd.2006.12.014 PubMed DOI

Seong Y. J., Alhashimi M., Mayhoub A., Mohammad H., Seleem M. N. (2020). Repurposing fenamic acid drugs to combat multidrug-resistant Neisseria gonorrhoeae. Antimicrob Agents Chemother . Antimicrob. Agents Chemother. 64, e02206. 10.1128/AAC.02206-19 PubMed DOI PMC

Shah P. N., Marshall-Batty K. R., Smolen J. A., Tagaev J. A., Chen Q., Rodesney C. A., et al. (2018). Antimicrobial activity of ibuprofen against cystic fibrosis-associated gram-negative pathogens. Antimicrob. Agents Chemother. 62, e01574. 10.1128/AAC.01574-17 PubMed DOI PMC

Shaw C. F. (1999). Gold-based therapeutic agents. Chem. Rev. 99, 2589–2600. 10.1021/cr980431o PubMed DOI

Shirin H., Moss S. F., Kancherla S., Kancherla K., Holt P. R., Weinstein I. B., et al. (2006). Non-steroidal anti-inflammatory drugs have bacteriostatic and bactericidal activity against Helicobacter pylori . J. Gastroenterol. Hepatol. 21, 1388–1393. 10.1111/j.1440-1746.2006.04194.x PubMed DOI

Silverstein F. E., Faich G., Goldstein J. L., Simon L. S., Pincus T., Whelton A., et al. (2000). Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284, 1247–1255. 10.1001/jama.284.10.1247 PubMed DOI

Singh J. A., Yu S. (2018). Septic arthritis in emergency departments in the us: a national study of health care utilization and time trends. Arthritis Care Res. Hob. 70, 320–326. 10.1002/acr.23270 PubMed DOI

Slomovitz B. M., Broaddus R. R., Schmandt R., Wu W., Oh J. C., Ramondetta L. M., et al. (2004). Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. Gynecol. Oncol. 95, 32–36. 10.1016/j.ygyno.2004.06.052 PubMed DOI

Smith M., Roberts M., Al-Kassas R. (2022). Implantable drug delivery systems for the treatment of osteomyelitis. Drug Dev. Ind. Pharm. 48, 511–527. 10.1080/03639045.2022.2135729 PubMed DOI

Song J. H., Ko K. S., Suh J. Y., Oh W. S., Kang C. I., Chung D. R., et al. (2008). Clinical implications of vancomycin-resistant Enterococcus faecium (VRE) with VanD phenotype and vanA genotype. J. Antimicrob. Chemother. 61, 838–844. 10.1093/jac/dkn025 PubMed DOI

Song Y., Baer M., Srinivasan R., Lima J., Yarranton G., Bebbington C., et al. (2012). PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice. Eur. J. Clin. Microbiol. Infect. Dis. 31, 1837–1845. 10.1007/s10096-011-1509-2 PubMed DOI

Sood S., Yadav A., Shrivastava R. (2016). Mycobacterium aurum is unable to survive Mycobacterium tuberculosis latency associated stress conditions: implications as non-suitable model organism. Indian J. Microbiol. 56, 198–204. 10.1007/s12088-016-0564-x PubMed DOI PMC

Sozer S., Diniz G., Lermioglu F. (2011). Effects of celecoxib in young rats: histopathological changes in tissues and alterations of oxidative stress/antioxidant defense system. Arch. Pharm. Res. 34, 253–259. 10.1007/s12272-011-0211-3 PubMed DOI

Spitaleri A., Ghodousi A., Miotto P., Cirillo D. M. (2019). Whole genome sequencing in Mycobacterium tuberculosis. ann transl med . Ann. Transl. Med. 7, S197. 10.21037/atm.2019.07.28 PubMed DOI PMC

Stahl S. M., Pradko J. F., Haight B. R., Modell J. G., Rockett C. B., Learned-Coughlin S. (2004). A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim. Care Companion J. Clin. Psychiatry 6, 159–166. 10.4088/pcc.v06n0403 PubMed DOI PMC

Stanbury R. M., Graham E. M. (1998). Systemic corticosteroid therapy-side effects and their management. Br. J. Ophthalmol. 82, 704–708. 10.1136/bjo.82.6.704 PubMed DOI PMC

Steinman M. A., Landefeld C. S., Rosenthal G. E., Berthenthal D., Sen S., Kaboli P. J. (2006). Polypharmacy and prescribing quality in older people. J. Am. Geriatr. Soc. 54, 1516–1523. 10.1111/j.1532-5415.2006.00889.x PubMed DOI

Svensson E. M., Murray S., Karlsson M. O., Dooley K. E. (2015). Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. J. Antimicrob. Chemother. 70, 1106–1114. 10.1093/jac/dku504 PubMed DOI PMC

Tabacco G., Bilezikian J. P. (2019). Osteoanabolic and dual-action drugs. Br. J. Clin. Pharmacol. 85, 1084–1094. 10.1111/bcp.13766 PubMed DOI PMC

Tabatabaeifar F., Isaei E., Kalantar-Neyestanaki D., Morones-Ramírez J. R. (2022). Antimicrobial and antibiofilm effects of combinatorial treatment formulations of anti-inflammatory drugs-common antibiotics against pathogenic bacteria. Pharmaceutics 15, 4. 10.3390/pharmaceutics15010004 PubMed DOI PMC

Tahan T. T., Gabardo B. M. A., Rossoni A. M. O. (2020). Tuberculosis in childhood and adolescence: a view from different perspectives. J. Pediatr. Rio J. 96 (1), 99–110. 10.1016/j.jped.2019.11.002 PubMed DOI PMC

Takahashi O., Hiraga K. (1985). Differences in the haemorrhagic toxicity of aspirin between rats and mice. Acta Pharmacol. Toxicol. (Copenh) 56, 6–13. 10.1111/j.1600-0773.1985.tb01246.x PubMed DOI

Tarkowski A. (2006). Infection and musculoskeletal conditions: infectious arthritis. Best. Pract. Res. Clin. Rheumatol. 20, 1029–1044. 10.1016/j.berh.2006.08.001 PubMed DOI

Taylor R. S., Fotopoulos G., Maibach H. (2011). Safety profile of topical diclofenac: a meta-analysis of blinded, randomized, controlled trials in musculoskeletal conditions. Curr. Med. Res. Opin. 27, 605–622. 10.1185/03007995.2010.550606 PubMed DOI

Thangamani S., Maland M., Mohammad H., Pascuzzi P. E., Avramova L., Koehler C. M., et al. (2017). Repurposing approach identifies auranofin with broad spectrum antifungal activity that targets Mia40-Erv1 pathway. Front. Cell Infect. Microbiol. 7, 4. 10.3389/fcimb.2017.00004 PubMed DOI PMC

Thangamani S., Mohammad H., Abushahba M. F., Sobreira T. J., Hedrick V. E., Paul L. N., et al. (2016a). Antibacterial activity and mechanism of action of auranofin against multi-drug-resistant bacterial pathogens. Sci. Rep. 6, 22571. 10.1038/srep22571 PubMed DOI PMC

Thangamani S., Mohammad H., Abushahba M. F., Sobreira T. J., Seleem M. N. (2016b). Repurposing auranofin for the treatment of cutaneous staphylococcal infections. Int. J. Antimicrob. Agents 47, 195–201. 10.1016/j.ijantimicag.2015.12.016 PubMed DOI PMC

Thangamani S., Younis W., Seleem M. N. (2015). Repurposing celecoxib as a topical antimicrobial agent. Front. Microbiol. 6, 750. 10.3389/fmicb.2015.00750 PubMed DOI PMC

Tong S. Y. C., Davis J. S., Eichenberger E., Holland T. L., Fowler V. G. (2015). Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin. Microbiol. Rev. 28, 603–661. 10.1128/CMR.00134-14 PubMed DOI PMC

Urish K. L., Cassat J. E. (2020). Staphylococcus aureus osteomyelitis: bone, bugs, and surgery. Infect. Immun. 88, 009322-19. 10.1128/IAI.00932-19 PubMed DOI PMC

Van Norman G. A. (2019). Limitations of animal studies for predicting toxicity in clinical trials: is it time to rethink our current approach? JACC Basic Transl. Sci. 4, 845–854. 10.1016/j.jacbts.2019.10.008 PubMed DOI PMC

Vargason A. M., Anselmo A. C., Mitragotri S. (2021). The evolution of commercial drug delivery technologies. Nat. Biomed. Eng. 5, 951–967. 10.1038/s41551-021-00698-w PubMed DOI

Verma T., Bhaskarla C., Sadhir I., Sreedharan S., Nandi D. (2018). Non-steroidal anti-inflammatory drugs, acetaminophen and ibuprofen, induce phenotypic antibiotic resistance in Escherichia coli: roles of marA and acrB . FEMS Microbiol. Lett. 365, 10.1093/femsle/fny251 PubMed DOI

Vik I., Bollestad M., Grude N., Bærheim A., Damsgaard E., Neumark T., et al. (2018). Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women-A double-blind, randomized non-inferiority trial. PLoS Med. 15, e1002569. 10.1371/journal.pmed.1002569 PubMed DOI PMC

Vilaplana C., Marzo E., Tapia G., Diaz J., Garcia V., Cardona P. J. . (2013). Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J. Infect. Dis. 208, 199–202. 10.1093/infdis/jit152 PubMed DOI

Walter N., Baertl S., Alt V., Rupp M. (2021). What is the burden of osteomyelitis in Germany? An analysis of inpatient data from 2008 through 2018. BMC Infect. Dis. 21, 550. 10.1186/s12879-021-06274-6 PubMed DOI PMC

Whittle B. J. (2000). COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors. Gut 47, 320–325. 10.1136/gut.47.3.320 PubMed DOI PMC

Wu H., Kouladjian O'Donnell L., Fujita K., Masnoon N., Hilmer S. N. (2021). Deprescribing in the older patient: a narrative review of challenges and solutions. Int. J. Gen. Med. 14, 3793–3807. 10.2147/IJGM.S253177 PubMed DOI PMC

Yao C., Narumiya S. (2019). Prostaglandin-cytokine crosstalk in chronic inflammation. Br. J. Pharmacol. 176, 337–354. 10.1111/bph.14530 PubMed DOI PMC

Yin Z., Wang Y., Whittell L. R., Jergic S., Liu M., Harry E., et al. (2014). DNA replication is the target for the antibacterial effects of nonsteroidal anti-inflammatory drugs. Chem. Biol. 21, 481–487. 10.1016/j.chembiol.2014.02.009 PubMed DOI

Zhang H., Liu S., Yue J., Sun S., Lv Q., Jian S., et al. (2019). In vitro, antimicrobial activity of diacerein on 76 isolates of gram-positive cocci from bacterial keratitis patients and in vivo study of diacerein eye drops on Staphylococcus aureus keratitis in mice. Antimicrob. Agents Chemother. 63, 018744-18–e1918. 10.1128/AAC.01874-18 PubMed DOI PMC

Zhang L., Lu Y. M., Dong X. Y. (2004). Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid. Chin. J. Dig. Dis. 5, 110–114. 10.1111/j.1443-9573.2004.00164.x PubMed DOI

Zhang S., Qu X., Tang H., Wang Y., Yang H., Yuan W., et al. (2021). Diclofenac resensitises methicillin-resistant Staphylococcus aureus to β-Lactams and prevents implant infections. Adv. Sci. (Weinh) 8, 2100681. 10.1002/advs.202100681 PubMed DOI PMC

Zumla A., Maeurer M., Host-Directed T. N., Chakaya J., Hoelscher M., Ntoumi F., et al. (2015). Towards host-directed therapies for tuberculosis. Nat. Rev. Drug Discov. 14, 511–512. 10.1038/nrd4696 PubMed DOI